IPO Rating: City Therapeutics Inc.
✓ IPO Prophet Rating: 7.55/10 🏦 Deal Quality & Underwriters: 8.30/10 City Therapeutics is offering 9.72 million all-primary shares at...
43 Views
City Therapeutics (CTY) Eyes $175 Million IPO to Advance Next-Generation RNAi Medicines
City Therapeutics (CTY) , a Cambridge, Massachusetts-based biotechnology company, plans to list on the Nasdaq Global Market , offering 9,722,222...
46 Views
City Therapeutics (CTY): Big-Name Backers, Early-Stage Science and an Aftermarket Test
City Therapeutics pairs an RNAi platform with Biogen and Bausch + Lomb partnerships, but early-stage science and weak biotech IPO trading temper...
60 Views
IPO Databook: City Therapeutics (CTY US) - Oct 2026
City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics to silence disease-relevant proteins,...
83 Views
City Therapeutics (CTY US): Synthetic Expert Call Transcript (10 Oct 2026)
City Therapeutics is transitioning from a discovery-stage platform story to a clinical-stage execution story with its pending $175 million IPO at...
85 Views